IQ-AI says leading US cancer centre has bought subsidiary’s unique brain imaging technology

IQ-AI Limited (LON:IQAI) said the Montgomery Cancer Center in Alabama has bought its Imaging Biometrics subsidiary’s IB Clinic product.

The software suite includes the IB Neuro and IB Delta T1 mapping algorithms, which IQ-AI said, “continue to gain acceptance in brain tumour imaging and assessment”.

The latter offers an “objective and rapid visual assist” for neuroradiologists that helps identify subtle regions of contrast enhancement on routine MR images.

It also assists in eliminating “confounding factors” such as post-surgical blood products and other “artefacts”.

IB Neuro’s blood volume maps, meanwhile, are used to help assess whether a treatment is having an effect on the tumour.